The efficacy of maintenance therapy in ulcerative colitis is influenced by the pharmacokinetics of mesalazine and by adherence to medicamentous therapy

Commentary to the PODIUM study

Česká verzia

Authors: M. Lukáš
Authors place of work: Klinické a výzkumné centrum pro střevní zánět ISCARE a 1. LF UK v Praze Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2010; 64(5): 26-29
Category: IBD

Summary

In the last year the results of the PODIUM trial were published. The authors investigated the efficacy and safety of once and twice daily administration of prolonged-release mesalazine granules (2 g daily) in the maintenance of remission in patients with quiescent ulcerative colitis. It has been shown that once daily oral mesalazine had better therapeutic results compared with patients given oral mesalazine of 1 g twice daily. The commentary discusses the possibilities explaining the positive effect of a single dose administration of the drug. The most important seems to be the positive impact on mesalazine pharmacokinetics and the significantly better adherence of patients to medicamentous therapy.

Key words:
inflammatory bowel disease – ulcerative colitis – maintenance therapy – mesalazine

Zdroje

1. Dignass AU, Bokemeyer B, Adamek H et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7(7): 762–769.

2. Diagnass AU, VanAsche G, Linday JO et al. The second European evidence based konsensus on the diagnosis and management of Crohn´s Disease. Current management. Journal of Crohn´s and Colitis 2010; 4(1): 28–62.

3. Lukáš M. Idiopatické střevní záněty a kolorektálním karcinom. Nové souvislosti a další perspektivy. Čes a slov gastroenterol hepatol 2006; 6(3):113–118.

4. D´Inca. Concentration of 5-ASA in large bowel mucosa correlates with clinical efficacy in UC patients. DDW 2008 San Diego. Gastroenterology 2008; 134: S1230

5. Kruis W, Kiudelis G, Racz I et al. Once-daily versus free-times-daily mesalazine granules i nactive ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58(2): 233–240.

6. Červený P, Bortlík M, Kuběna A et al. Non-adherence in IBD: results of factors analysis. IBD 2007; 13(10): 1244–1249.